J0576 — Injection, buprenorphine extended-release (brixadi), 1 mg
J0576 is a HCPCS Level II code for injection, buprenorphine extended-release (brixadi), 1 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on March 31, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated J0576 on March 31, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J0576
- Long descriptor
- Injection, buprenorphine extended-release (brixadi), 1 mg
- Short descriptor
- Inj buprenorph (brixadi) 1mg
- Added
- January 1, 2024
- Terminated
- March 31, 2024
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J0576
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J0576 is not quite right, the correct code is very often within a few positions of it.
- J0565Injection, bezlotoxumab, 10 mg
- J0567Injection, cerliponase alfa, 1 mg
- J0570Buprenorphine implant, 74.2 mg
- J0571Buprenorphine, oral, 1 mg
- J0572Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine
- J0573Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine
- J0574Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine
- J0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
- J0577Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
- J0578Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy
- J0582Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
- J0583Injection, bivalirudin, 1 mg
- J0584Injection, burosumab-twza 1 mg
- J0585Injection, onabotulinumtoxina, 1 unit
- J0586Injection, abobotulinumtoxina, 5 units
- J0587Injection, rimabotulinumtoxinb, 100 units
Questions about J0576
What is HCPCS code J0576?
J0576 is a HCPCS Level II code for injection, buprenorphine extended-release (brixadi), 1 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J0576?
The CMS HCPCS file marks J0576 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J0576 still valid?
No. J0576 was terminated on March 31, 2024 and should not be used on new claims.